Nanjing Hanxin Pharmaceutical Technology co.,Ltd.

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes mellitus and for chronic weight management . It integrates the actions of both incretins into a single molecule, offering improved glycemic control alongside significant weight loss benefits . Clinical trials have demonstrated that tirzepatide can lead to substantial reductions in HbA1c levels and body weight compared to other antidiabetic agents, with effects sustained over time . The medication is administered once weekly via subcutaneous injection, making it a convenient option for patients. However, like other GLP-1 receptor agonists, it may cause side effects such as nausea, vomiting, and diarrhea, which are generally mild to moderate in severity . Given its potent efficacy profile, tirzepatide represents a significant advancement in the therapeutic landscape for managing both diabetes and obesity.